Which funds bought or sold CRNXGBP in Q3 2026?
Crinetics Pharmaceuticals In. 0 funds bought, 11 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$1.3B.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- FidelityOUT−$593M
- BlackRockOUT−$365M
- FarallonOUT−$336M
- WellingtonOUT−$267M
- VanguardOUT−$181M
- Vanguard CapitalOUT−$178M
- GeodeOUT−$102M
- State StreetOUT−$101M
- T. Rowe PriceOUT−$75M
- Northern TrustOUT−$36M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (0)
None of the tracked funds.
Sold (11)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Fidelity Asset manager | Sold out | −$593M | — |
| BlackRock Index giant | Sold out | −$365M | — |
| Farallon Hedge fund | Sold out | −$336M | — |
| Wellington Asset manager | Sold out | −$267M | — |
| Vanguard Index giant | Sold out | −$181M | — |
| Vanguard Capital Index giant | Sold out | −$178M | — |
| Geode Index giant | Sold out | −$102M | — |
| State Street Index giant | Sold out | −$101M | — |
| T. Rowe Price Asset manager | Sold out | −$75M | — |
| Northern Trust Bank & broker | Sold out | −$36M | — |
| Fisher Investments Asset manager | Sold out | −$28M | — |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.